IPCA Laboratories Limited has informed the Exchange regarding a press release dated Jun 12, 2026, titled "Licensing agreement granting Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialization of multiple monoclonal antibody products targeting oncology and inflammatory diseases. ".